Algen Biotechnologies vs Isomorphic Labs

Side-by-side comparison of features, pricing, and ratings

Analysis reviewed Live tool data as of 2026-10-09
Cross-checked through our multi-step verification ·
Saved

At a glance

DimensionAlgen BiotechnologiesIsomorphic Labs
Core TechnologyAlgenCRISPR gene modulation + AlgenBrain AI (deep learning on gene expression)AlphaFold + Drug Design Engine (predictive & generative AI for molecules)
Best ForTarget discovery via CRISPR gene modulation in cancer & inflammationLead optimization & molecule design for large pharma programs
Not ForSmall labs without advanced genomics infrastructureIndividual researchers or self-service users

Algen Biotechnologies is ideal for target discovery using CRISPR-based gene modulation, backed by a $555M AstraZeneca deal. Isomorphic Labs excels in molecule design and optimization, powered by AlphaFold and partnerships with Novartis and J&J. Choose Algen for early-stage target identification in immunology/oncology; choose Isomorphic for late-stage drug design and lead optimization.

Algen Biotechnologies
Algen Biotechnologies

AI-CRISPR target discovery platform used by pharma partners to find causal immunology and oncology targets before committing to a program.

Visit Website
Isomorphic Labs
Isomorphic Labs

Isomorphic Labs applies generative AI drug discovery to design novel molecules and predict how candidates will perform.

Visit Website
Pricing
Contact Sales
Contact Sales
Plans
—
—
Popularity
8 views
7.5k views
Skill Level
Advanced
Advanced
API Available
Platforms
Web
—
Categories
🧬 Drug Discovery & Life Sciences
🧬 Drug Discovery & Life Sciences
Features
AlgenCRISPR proprietary next-generation CRISPR gene-modulation system
Fine-tuned and precise gene modulation to deconvolute complex biology
AlgenBrain AI foundation model predicting RNA signaling networks
Proprietary deep learning models trained on billions of real-time gene expression changes
Models capture dynamic expression changes throughout disease progression
Industrial-scale single-cell gene modulation
Multi hundred-thousand gene-modulated cell fates processed
Reverse engineers disease trajectory to surface causal biology
Illuminates disease-driving RNA signaling pathways
High-confidence, scaled causal biology output for drug discovery
Human-centric therapeutic endpoints for target discovery
Therapeutic target identification for immunology indications
Therapeutic target identification for oncology indications
Partnership-based drug discovery collaborations
Platform rooted in UC Berkeley CRISPR research from Jennifer Doudna's lab
Drug Design Engine spanning generative molecule design through lead optimization
Predictive AI models that anticipate how candidate drugs will perform
Generative models for designing novel molecules
Builds on and beyond the Nobel-winning AlphaFold system
End-to-end research collaborations from target identification to lead optimization
Digital biology approach aimed at discovery at digital speed
Named pharma partners include Johnson & Johnson, Novartis and Eli Lilly
Joined the Virtual Biology Initiative to build foundational data for AI disease models
Funder of Biohub's $1.8B initiative to train AI models that predict cell behavior
Bioresilience framework for biological threats and health emergencies
Series B investment round announced May 2026 to scale the Drug Design Engine
Follows a $600M external raise in March 2025
President Max Jaderberg appointed November 2025 to integrate AI and science
Interdisciplinary team of drug discovery experts and ML specialists
Founded by Demis Hassabis, who serves as CEO

What real users say: Algen Biotechnologies vs Isomorphic Labs

Not marketing copy and not our opinion — a structured sweep of public discussion (reviews, forums, communities and video comments), showing what people praise and what they complain about for each tool.

Algen Biotechnologies

20 mentions across 1 sources · 30% positive — critical (averaged across 1 source)

YouTube

What users praise

  • • Backed by Nobel Laureate Jennifer Doudna's lab, adding credibility.
  • • $555M AstraZeneca partnership validates enterprise-grade trust.
  • • AlgenCRISPR enables precise, next-generation gene modulation.
  • • AlgenBrain processes billions of gene expression changes for targets.

What frustrates them

  • • Unavailable to individual researchers or small labs.
  • • No public pricing or self-serve option; partnership-only model.
  • • Negative sentiment from public confusion with algae fuel.
  • • Skepticism about real-world efficiency and commercial viability.

Researched Aug 2, 2026

Isomorphic Labs

No verifiable community signal. We scanned public discussion on Oct 7, 2026 and found posts matching the name “Isomorphic Labs”, but could not establish that they are about this product rather than something else sharing its name. Rather than publish a score built on the wrong subject, we publish none.

Who should pick which

  • Pharma R&D team targeting immunology
    Pick: Algen Biotechnologies

    Algen's AI-driven CRISPR platform reverse engineers disease trajectory for causal target discovery in immunology, as validated by its $555M AstraZeneca partnership.

  • Large pharma optimizing late-stage leads
    Pick: Isomorphic Labs

    Isomorphic's Drug Design Engine with AlphaFold accelerates lead optimization and molecule design, backed by Novartis and J&J collaborations.

  • Cancer research enterprise
    Pick: Algen Biotechnologies

    Algen's focus on cancer and inflammation, using single-cell gene modulation and causal biology, is directly suited for oncology target discovery.

  • Biotech startup needing molecule design
    Pick: Isomorphic Labs

    Isomorphic's generative AI and predictive models enable rapid design of novel molecules, but only through large pharma partnerships; not for small startups.

Frequently Asked Questions

Algen Biotechnologies vs Isomorphic Labs: which should you choose?

Algen Biotechnologies is ideal for target discovery using CRISPR-based gene modulation, backed by a $555M AstraZeneca deal. Isomorphic Labs excels in molecule design and optimization, powered by AlphaFold and partnerships with Novartis and J&J. Choose Algen for early-stage target identification in immunology/oncology; choose Isomorphic for late-stage drug design and lead optimization.

Which tool is better for identifying new drug targets?

Algen Biotechnologies, with its AlgenBrain AI and CRISPR gene modulation, is specifically built for causal target discovery in immunology and oncology.

Which company has a stronger AI foundation?

Both use cutting-edge AI. Isomorphic benefits from DeepMind's AlphaFold (Nobel Prize-winning), while Algen uses proprietary deep learning on gene expression. The choice depends on application.

Can small biotechs use these tools?

No. Both require enterprise-level partnerships. Algen's platform demands advanced genomics infrastructure, and Isomorphic works only through large pharma collaborations.

What are the recent major partnerships?

Algen partnered with AstraZeneca in October 2025 for immunology (up to $555M). Isomorphic collaborated with Johnson & Johnson in January 2026 and has Novartis deals.

Do they offer software or APIs?

Neither offers self-service software or APIs. Access is through partnership agreements only.

Which company has more funding?

Isomorphic Labs raised $600M in external investment (2025) plus a Series B (2026). Algen's disclosed funding is the $555M AstraZeneca partnership.

Are these tools applicable to rare diseases?

Algen's focus on causal biology could be applied to rare diseases with genetic underpinnings. Isomorphic's molecule design could be used for any disease, but only through partnerships.

Which is more mature?

Isomorphic Labs leverages mature AlphaFold technology and has secured multiple pharma collaborations. Algen is newer but validated by a major pharma deal.

More Algen Biotechnologies or Isomorphic Labs comparisons

Explore each tool further

Browse these categories

Still deciding? Get the weekly AI tools brief

One email a week — new tools, honest comparisons, no spam.

Last reviewed: July 3, 2026